BRIEF—3SBio and Verseau Therapeutics to collaborate on I-O therapies

China’s 3SBio and Verseau Therapeutics have inked a deal to develop and sell novel immuno-oncology biologics to treat a broad range of cancers.

The firms will leverage Verseau's proprietary drug discovery platform, which generates macrophage checkpoint modulators (MCMs).

3SBio will receive an exclusive license to develop and commercialize a select number of candidates in China and Taiwan, while Verseau will be responsible for discovery and optimization of MCM antibodies for each program.

3SBio will also purchase $15 million of Verseau series B preferred stock. Additional financial terms were not disclosed.